precisionmedicineonline4d
FDA Approves New 'Vanza Triple' Cystic Fibrosis Drug From Vertex, Expands Label for Trikafta
Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.
precisionmedicineonline4d
BMS's Opdivo-Yervoy Combo Approved in Europe for First-Line Treatment of Certain Colorectal Cancers
NEW YORK – Bristol Myers Squibb on Monday said the European Commission approved its PD-1 inhibitor Opdivo (nivolumab) plus the CTLA-4 inhibitor Yervoy (ipilimumab) as a first-line treatment for ...
precisionmedicineonline4d
European Commission Approves AstraZeneca's Tagrisso in Unresectable EGFR-Mutated NSCLC
NEW YORK – AstraZeneca on Monday said the European Commission approved its tyrosine kinase inhibitor Tagrisso (osimertinib) as a treatment for patients with advanced, unresectable non-small cell lung ...
precisionmedicineonline9d
Gene Therapy in 2024: 'Persistent' Approvals, Layoffs, and In Vivo Moving Toward the Clinic
NEW YORK – 2024 was a banner year of "firsts" in the gene therapy space, as the US Food and Drug Administration greenlit ...
precisionmedicineonline8d
Senti Biosciences, Celest Therapeutics Treat First Patient With CAR-NK Cell Therapy in China
The firms have teamed up on a Phase I trial to evaluate the off-the-shelf cell therapy SN301A in patients with advanced GPC3-expressing liver cancers.
precisionmedicineonline7d
Institute for Follicular Lymphoma Innovation Invests $11M in PeproMene Bio's CAR T-Cell Therapy
NEW YORK – The Institute for Follicular Lymphoma Innovation (IFLI) is investing $11 million to advance PeproMene's BAFF-R targeting CAR T-cell therapy, PMB-CT01, as a treatment for patients with ...